Faraday Future Delivers First Robots in Middle East, Plans September Launches 
France Targets Shein, Temu With Fast-Fashion Fees 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
OpenAI Nears Astra AI Model Launch With Safety Focus 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Add as a preferred source on Google
VANCOUVER, British Columbia, March 21, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 17th Annual Needham Healthcare Conference in New York on Wednesday, March 28th 2018.
Aquinox Presentation Details
Date: Wednesday, March 28th 2018
Time: 2:00 pm Eastern Time / 11:00 am Pacific Time
Location: New York, NY – Westin New York Grand Central
A live audio webcast and archive of the event will be available at:
http://wsw.com/webcast/needham86/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
